These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 29578287)

  • 1. Enhanced spectrofluorimetric determination of two novel combination therapies for the treatment of benign prostatic hyperplasia containing tamsulosin hydrochloride.
    El-Kimary EI; Khamis EF; Belal SF; Abdel Moneim MM
    Luminescence; 2018 Jun; 33(4):771-779. PubMed ID: 29578287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fourier convolution versus derivative spectrophotometry: Application to the analysis of two binary mixtures containing tamsulosin hydrochloride as a minor component.
    El-Kimary EI; Khamis EF; Belal SF; Abdel Moneim MM
    Ann Pharm Fr; 2020 Mar; 78(2):129-141. PubMed ID: 32070480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Nazir J; Heemstra L; van Engen A; Hakimi Z; Ivanescu C
    BMC Urol; 2015 May; 15():41. PubMed ID: 25956727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia.
    Dimitropoulos K; Gravas S
    Drug Des Devel Ther; 2015; 9():1707-16. PubMed ID: 25834406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Green & Sensitive pH-dependent Spectrofluorimetric Assay of Tamsulosin Hydrochloride and Tadalafil in their New Combined Formulation for Benign Prostatic Hyperplasia: Application to Spiked Human Plasma.
    Abdel Moneim MM
    J Fluoresc; 2022 Jul; 32(4):1581-1590. PubMed ID: 35576092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assay of new combination of tamsulosin and tadalafil using synchronous spectrofluorimetric method coupled with mathematical tools.
    M Youssef R; Abdelhafez AM; Hassan EM; Gawad DA
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Apr; 271():120904. PubMed ID: 35104741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Validated HPTLC Method for the Analysis of Two Binary Mixtures Containing Tamsulosin Hydrochloride with Antimuscarinic Agents.
    El-Kimary EI; Khamis EF; Belal SF; Abdel Moneim MM
    J Chromatogr Sci; 2018 Jan; 56(1):81-91. PubMed ID: 28977351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage.
    Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Prokofyeva A; Loparev S
    Aging Male; 2018 Jun; 21(2):121-129. PubMed ID: 29113548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micellar-enhanced and green-assessed first-derivative synchronous spectrofluorimetric approach for concurrent determination of alfuzosin hydrochloride and solifenacin succinate in different matrices: Docking simulation.
    Sayed RA; Mohamed AR; Shalaby A; Ibrahim H
    Spectrochim Acta A Mol Biomol Spectrosc; 2023 May; 293():122442. PubMed ID: 36758367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial.
    Cai JL; Zhou Z; Yang Y; Yan YF; Jing S; Na YQ
    Chin Med J (Engl); 2016 Dec; 129(24):2899-2906. PubMed ID: 27958220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of Tamsulosin Hydrochloride and Solifenacin Succinate by Discriminative Derivative Synchronous Emission Spectroscopy.
    Naraparaju S; Anumolu PKD; Gurrala S; Galennagari R
    Turk J Pharm Sci; 2018 Aug; 15(2):149-155. PubMed ID: 32454654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smart spectrophotometric assessment of tamsulosin hydrochloride and tadalafil in their new pharmaceutical formulation for treatment of benign prostatic hyperplasia and erectile dysfunction.
    Rezk MR; Tantawy MA; Wadie M; Weshahy SA
    Spectrochim Acta A Mol Biomol Spectrosc; 2020 Feb; 227():117547. PubMed ID: 31734571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence with solifenacin add-on therapy in men with benign prostate obstruction and residual symptoms of overactive bladder after tamsulosin monotherapy.
    Lee YS; Lee KS; Kim JC; Hong S; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK
    Int J Clin Pract; 2014 Dec; 68(12):1496-502. PubMed ID: 25284747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
    Barkin J; Diles D; Franks B; Berner T
    Can J Urol; 2015 Aug; 22(4):7914-23. PubMed ID: 26267031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder.
    Verheggen BG; Lee R; Lieuw On MM; Treur MJ; Botteman MF; Kaplan SA; Trocio JN
    J Med Econ; 2012; 15(3):586-600. PubMed ID: 22332704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smart UV spectrophotometric methods based on simple mathematical filtration and classical methods for the simultaneous determination of tamsulosin and solifenacin: A comparative study of efficacy and spectral resolution.
    El-Henawee MM; Abd El-Hay SS; Attala K; Eissa MS
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Feb; 247():119151. PubMed ID: 33188970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin.
    Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
    Aging Male; 2015 Mar; 18(1):44-8. PubMed ID: 25136746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.
    Drake MJ; Sokol R; Coyne K; Hakimi Z; Nazir J; Dorey J; Klaver M; Traudtner K; Odeyemi IA; Oelke M; van Kerrebroeck P;
    BJU Int; 2016 Jan; 117(1):165-72. PubMed ID: 25907003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.